Figure 5
Figure 5. Disruption of IL-17A signaling is protective in stroke. (A) Triphenyltetrazolium chloride (TTC) staining for evaluation of infarct volume at day 3 (left) and neurologic scores at days 1 and 3 (right) of wt and Il17ra−/− mice after MCAO. Data are represented as means ± SDs of 10 wt and 8 Il17ra−/− animals. (B) TTC staining evaluation of infarct volume at day 3 (left) and neurologic scores at days 1 and 3 (right) of wt animals that were treated intraperitoneally with 500 μg of anti–IL-17A (clone MM17F3) or isotype control antibodies 3 hours after onset of MCAO. Data show the means ± SDs of 6 animals per group. *P < .05, **P < .01 for infarct sizes (t test) and *P < .05 for neurologic scores (Mann-Whitney U test). Representative TTC-stained serial coronal 1-mm thick brain sections 3 days after MCAO to analyze infarct volume in wt mice, Il17ra−/− mice, wt treated with isotype control antibody, and wt mice treated with anti–IL-17A antibody.

Disruption of IL-17A signaling is protective in stroke. (A) Triphenyltetrazolium chloride (TTC) staining for evaluation of infarct volume at day 3 (left) and neurologic scores at days 1 and 3 (right) of wt and Il17ra−/− mice after MCAO. Data are represented as means ± SDs of 10 wt and 8 Il17ra−/− animals. (B) TTC staining evaluation of infarct volume at day 3 (left) and neurologic scores at days 1 and 3 (right) of wt animals that were treated intraperitoneally with 500 μg of anti–IL-17A (clone MM17F3) or isotype control antibodies 3 hours after onset of MCAO. Data show the means ± SDs of 6 animals per group. *P < .05, **P < .01 for infarct sizes (t test) and *P < .05 for neurologic scores (Mann-Whitney U test). Representative TTC-stained serial coronal 1-mm thick brain sections 3 days after MCAO to analyze infarct volume in wt mice, Il17ra−/− mice, wt treated with isotype control antibody, and wt mice treated with anti–IL-17A antibody.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal